Abstract
Naturally occurring antibodies (NAbs) play a vital role in the first line of defense against bacterial and viral infections. Most studies in mice and man have attributed this role to NAbs of the IgM isotype. However, there is also a significant amount of data on the anti-infectious function of NAbs of the IgG isotype. Most of these observations are derived from studies using a privileged source of NAbs, the pooled human IgG for intravenous application, IVIG. In addition to its use as a replacement in humoral immunodeficiencies, IVIG is extensively used in autoimmune and inflammatory diseases. The properties of NAbs, the principal components of IVIG, are considered crucial for their immune-regulatory properties, owing to their ability to recognize self-antigens and even autoantibodies. By virtue of these specificities for several cellular antigens, including exposed proteins that act as receptors for a variety of pathogens, certain NAbs in IVIG have a therapeutic role in preventing or modulating infections. We summarize in this chapter several examples that highlight the importance of NAbs in the control of certain bacterial and viral infections.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Coutinho A, Kazatchkine MD, Avrameas S. Natural autoantibodies. Curr Opin Immunol 1995; 7:812–8. doi: 10.1016/0952-7915(95)80053-0 PMID:8679125
Hayakawa K, Asano M, Shinton SA et al. Positive selection of natural autoreactive B cells. Science 1999; 285:113–6. doi:10.1126/science.285.5424.113 PMID: 10390361
Ochsenbein AF, Fehr T, Lutz C et al. Control of early viral and bacterial distribution and disease by natural antibodies. Science 1999; 286:2156–9. doi: 10.1126/science.286.5447.2156 PMID: 10591647
Bartlett JG, Perl TM. The new Clostridium difficile-what does it mean? N Engl J Med 2005; 353:2503–5. doi: 10.1056/NEJMe058221 PMID: 16322604
Wilcox MH. Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhea. J Antimicrob Chemother 2004; 53:882–4. doi:10.1093/jac/dkh176 PMID:15073160
McPherson S, Rees CJ, Ellis R et al. Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridiumdifficile diarrhea. Dis Colon Rectum 2006; 49:640–5. doi:10.1007/sl0350-006-0511-8 PMID: 16525744
Hassett J, Meyers S, McFarland L et al. Recurrent Clostridium difficile infection in a patient with selective IgGl deficiency treated with intravenous immune globulin and Saccharomyces boulardii. Clin Infect Dis 1995; 20:S266–8. doi:10.1093/clinids/20.Supplement_2.S266 PMID:7548571
Gerding DN, Muto CA, Owens RC Jr. Treatment of Clostridium difficile infection. Clin Infect Dis 2008; 46:S32–42. doi: 10.1086/521860 PMID: 18177219
WHO. Dengue haemorrhagic fever: diagnosis, treatment, prevention and control. 2nd ed. Geneva: World Health Organization; 1997.
Halstead SB. Dengue. Lancet 2007; 370:1644–52. doi:10.1016/S0140-6736(07)61687-0 PMID: 17993365
Schexneider KI, Reedy EA. Thrombocytopenia in dengue fever. Curr Hematol Rep 2005; 4:145–8. PMID: 15720964
McMillan R. Chronicidiopathic thrombocytopenic purpura. N Engl J Med 1981; 304:1135–47. doi:10.1056/NEJM198105073041904 PMID:7012619
Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002; 346:995–1008. doi: 10.1056/NEJMra010501 PMID: 11919310
Oishi K, Inoue S, Cinco MT et al. Correlation between increased platelet-associated IgG and thrombocytopenia insecondary dengue virus infections. J Med Virol 2003; 71:259–64. doi: 10.1002/jmv. 10478 PMID: 12938201
Saito M, Oishi K, Inoue S et al. Association of increased platelet-associated immunoglobulins with thrombocytopenia and the severity of disease in secondary dengue virus infections. Clin Exp Immunol 2004; 138:299–303. doi: 10.1111/J.1365-2249.2004.02626.X PMID:15498040
Honda S, Saito M, Dimaano EM et al. Increased Phagocytosis of Platelets from Patients with Secondary Dengue Virus Infection by Human Macrophages. Am J Trop Med Hyg 2009; 80:841–5. PMID: 19407135
Ascher DP, Laws HF, Haves CG. The use of intravenous gammaglobulin in dengue fever, a case report. Southeast Asian J Trop Med Public Health 1989; 20:549–54. PMID:2484144
Ostronoff M, Ostronoff F, Florencio R et al. Serious thrombocytopenia due to dengue hemorrhagic fever treated with high dosages of immunoglobulin. Clin Infect Dis 2003; 36:1623–4. doi: 10.1086/374870 PMID: 12802766
Dimaano EM, Saito M, Honda S et al. Lack of efficacy of high-dose intravenous immunoglobulin treatment of severe thrombocytopenia in patients with secondary dengue virus infection. Am J Trop Med Hyg 2007; 77:1135–8. PMID:18165536
Lin CF, Lei HY, Liu CC et al. Generation of IgM anti-platelet autoantibody in dengue patients. J Med Virol 2001; 63:143–9. doi:10.1002/1096-9071(20000201)63:2<143::AID-JMV1009>3.0.CO;2-L PMID: 11170051
Sibéril S, Elluru SR, Negi VS et al. Intravenous immunoglobulin in autoimmune andinflammatory diseases: more than mere transfer of antibodies. Transfus Apheresis Sci 2007; 37:103–7 doi: 10.1016/j.transci.2007.01.012.
Andersson U, Bjork L, Skansen-Saphir U et al. Pooled human IgG modulates cytokine production in lymphocytes and monocytes. Immunol Rev 1994; 139:21–42. doi: 10.111 l/j.l600-065X.1994.tb00855.x PMID:7927412
Cines DB, Bussel JB, Liebman HA et al. The ITP syndrome: pathogenic and clinical diversity. Blood 2009; 113:6511–21. doi:10.1182/blood-2009-01-129155 PMID:19395674
Avirutnan P, Punyanadee N, Noisaran S et al. Vascular leakage in severe dengue virus infections: a potential role for the nonstructural viral protein NS1 and complement. J Infect Dis 2006; 193:1078–88. doi: 10.1086/500949 PMID: 16544248
Kurane I. Dengue hemorrhagic fever with special emphasis on immunopathogenesis. Comp Immunol Microbiol Infect Dis 2007; 30:329–40. doi:10.1016/j.cimid.2007.05.010 PMID: 17645944
Malasit P. Complement and dengue hemorrhagic fever/dengue shock syndrome. Southeast Asian J Trop Med Public Health 1987; 18:316–20. PMID:3501613
Morrison TE, Heise MT. The host complement system and arbovirus pathogenesis. Curr Drug Targets 2008; 9:165–72. doi: 10.2174/138945008783502485 PMID:18288968
Bokisch VA, Muller-Eberhard HJ, Dixon FJ. The role of complement in hemorrhagic shock syndrome (dengue). Trans Assoc Am Physicians 1973; 86:102–10. PMID:4132983
Avirutnan P, Punyadee N, Noisakran S et al. Vascular leakage in severe dengue virus infections: a potential role for the nonstructural viral protein NS1 and complement. J Infect Dis 2006; 193:1078–88. doi: 10.1086/500949 PMID: 16544248
Avirutnan P, Fuchs A, Hauhart RE et al. Antagonism of the complement component C4 by flavivirus nonstructural protein NS1. J Exp Med 2010; 207:793–806. doi:10.1084/jem.20092545 PMID:20308361
Green S, Rothman A. Immunopathological mechanisms in dengue and dengue hemorrhagic fever. Curr Opin Infect Dis 2006; 19:429–36. doi:10.1097/01.qco.0000244047.31135.faPMID:16940865
Lin CF, Lei HY, Shiau AL et al. Antibodies from dengue patient sera cross-react with endothelial cells and induce damage. J Med Virol 2003; 69:82–90. doi: 10.1002/jmv. 10261 PMID: 12436482
Morris SK, Dzolganovski B, Beyene J et al. A meta-analysis of the effect of antibody therapy for the prevention of severe respiratory syncytial virus infection. BMC Infect Dis 2009; 9:106–14. doi:10.1186/1471-2334-9-106 PMID:19575815
Razonable RR, Emery VC. Management of CMV infection and disease in transplant patients. Herpes 2004; 11:77–86. PMID: 15960905
Razonable RR, Paya CV. Herpesvirus infections in transplant recipients: current challenges in the clinical management of cytomegalovirus and Epstein-Barr virus infections. Herpes 2003; 10:60–5. PMID: 14759337
Bowman JS, Green M, Scnatlebury V et al. OKT3 and viral disease in pediatric liver transplant recipients. Clin Transplant 1991; 5:294–300. PMID:21170278
Gane E, Saliba F, Valdecasea G et al. Randomised trial of efficiacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver transplant recipients. Lancet 1997; 350:1729–33. doi: 10.1016/S0140-6736(97)05535-9PMID:9413463
Campbell AL, Herold BC. Strategies for the prevention of cytomegalovirus infection and disease in pediatric livertransplantationrecipients. Pediatr Transplant 2004; 8:619–27. doi: 10.1111/j.1399-3046.2004.00242.X PMID: 15598337
Snydman DR, McIver J, Leszczynski J et al. A pilot trial of a novel cytomegalovirus immune globulin in renal transplant recipients. Transplantation 1984; 38:553–7. doi: 10.1097/00007890-198411000-00026 PMID:6093299
Green M. Viral infections and pediatric liver transplantation. Pediatr Transplant 2002; 6:20–4. doi: 10.1034/j. 1399-3046.2002. 1p048.x PMID: 11906638
Snydman DR, Werner BG, Dougherty NN et al. Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1993; 119:984–91. PMID:8214995
Hurez V, Kaveri SV, Mouhoub A et al. Anti-CD4 activity of normal human immunoglobulin G for therapeutic use (intravenous immunoglobulin, IVIG). Ther Immunol 1994; 1:269–77. PMID:7584501
Kazatchkine MD, Kaveri SV. Immunomodulation of auto-immune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345:747–55. doi:10.1056/NEJMra993360 PMID: 11547745
Bouhlal H, Hocini H, Quillent-Gregoire C et al. Antibodies to C-C chemokine receptor 5 in normal human IgG block infection of macrophages and lymphocytes with primary R5-tropic strains of HIV-1. J Immunol 2001; 166:7606–11. PMID:11390517
Requena M, Bouhlal H, Nasreddine N et al. Inhibition of HIV-1 transmission in trans from dendritic cells to CD4+ T lymphocytes by natural antibodies to the CRD domain of DC-SIGN purified from breast milk and intravenous immunoglobulins. Immunology 2008; 123:508–18. doi:10.1111/j. 1365-2567.2007.02717.X PMID: 17999675
Moore JP, Trkola A, Dragic T. Co-receptors for HIV-1 entry. Curr Opin Immunol 1997; 9:551–62. doi:10.1016/S0952-7915(97)80110-0PMID:9287172
Deng, H., Liu R, Ellmeier W et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996; 381:661–6. doi:10.1038/381661a0 PMID:8649511
van’t Wout AB, Kootstra NA, Mulder-Kampinga GA et al. Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission. J Clin Invest 1994; 94:2060–7. doi:10.1172/JCI117560 PMID:7962552
Connor RI, Sheridan KE, Ceradini D et al. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 1997; 185:621–8. doi:10.1084/jem.l85.4.621 PMID:9034141
Rana S, Besson G, Cook DG et al. Role of CCR5 in infection of primary macrophages and lymphocytes by macrophage-tropic strains of human immunodeficiency virus: resistance to patient-derived and prototype isolates re-suiting from the ccr5 mutation. J Virol 1997; 71:3219–27. PMID:9060685
Samson M, Libert F, Doranz BJ et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 382:722–5. doi:10.1038/382722a0 PMID:8751444
Liu R, Paxton WA, Choe S et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996; 86:367–77. doi:10.1016/S0092-8674(00)80110-5 PMID:8756719
Cairns JS, D’Souza MP. Chemokines and HIV-1 second receptors: the therapeutic connection. Nat Med 1998; 4:563–8. doi:10.1038/nm0598-563 PMID:9585229
Clerici M, Barassi C, Devito C et al. Serum IgA of HIV-exposed uninfected individuals inhibit HIV through recognition of a region within the alpha-helix of gp41. AIDS 2002; 16:1731–41. doi: 10.1097/00002030-200209060-00004 PMID: 12218383
Lopalco L, Pastori C, Cosma A et al. Anti-cell antibodies in exposed seronegative individuals with HIV type 1-neutralizing activity. AIDS Res Hum Retroviruses 2000; 16:109–15. doi: 10.1089/088922200309458 PMID: 10659050
Lopalco L, Magnani Z, Confetti C et al. Anti-CD4 antibodies in exposed seronegative adults and in newborns of HIV type 1-seropositive mothers: a follow-up study. AIDS Res Hum Retroviruses 1999; 15:1079–85. doi:10.1089/088922299310377 PMID:10461828
Ditzel HJ, Rosenkilde MM, Garred P et al. The CCR5 receptor acts as an alloantigen in CCR5A32 homozygous individuals: identification of chemokine and HIV-1-blocking human antibodies. Proc Natl Acad Sci USA 1998; 95:5241–5. doi:10.1073/pnas.95.9.5241 PMID:9560260
Barassi C, Soprana E, Pastori C et al. Induction of murine mucosal CCR5-reactive antibodies as an anti-human immunodeficiency virus strategy. J Virol 2005; 79:6848–58. doi: 10.1128/JVI.79.11.6848-6858.2005 PMID: 15890924
Royce RA, Sena A, Cates W et al. Sexual transmissionofHIV. N Engl J Med 1997; 336:1072–8. doi:10.1056/NEJM199704103361507 PMID:9091805
Reece JC, Handley AJ, Anstee EJ et al. HIV-1 selection by epidermal dendritic cells during trans-mission across human skin. J Exp Med 1998; 187:1623–31. doi:10.1084/jem.l87.10.1623 PMID:9584140
Kahn JO, Walker BD. Acute human immunodeficiency virus type 1 infection. N Engl J Med 1998; 339:33–9. doi:10.1056/NEJM199807023390107 PMID:9647878
Hirsch VM, Sharkey ME, Brown CR et al. Vpx is required for dissemination and pathogenesis of SIV(SM) PBj: evidence of macrophage-dependent viral amplification. Nat Med 1998; 4:1401–8. doi:10.1038/3992 PMID:9846578
Zhang Z, Schuler T, Zupancic M et al. Sexual transmission and propagation of SIV and HIV in resting and activated CD4+T cells. Science 1999; 286:1353–7. doi: 10.1126/science.286.5443.1353 PMID:10558989
Olson WC, Rabut GE, Nagashima KA et al. Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5. J Virol 1999; 73:4145–55. PMID:10196311
Hurez V, Kaveri SV, Mouhoub A et al. Anti-CD4 activity of normal human immunoglobulins G for therapeutic use (intravenous immunoglobulin, IVIG). Ther Immunol 1994; 1:269–77. PMID:7584501
Piguet V, Blauvelt A. Essential roles for dendritic cells in the pathogenesis and potential treatment of HIV disease. J Invest Dermatol 2002; 119:365–9. doi:10.1046/j.l523-1747.2002.01840.xPMID:12190858
Belyakov IM, Berzofsky JA. Immunobiology of mucosal HIV infection and the basis for development of anew generation of mucosal AIDS vaccines. Immunity 2004; 20:247–53. doi: 10.1016/S1074-7613(04)00053-6 PMID: 15030769
Turville SG, Arthos J, Donald KM et al. HIV gpl20 receptors on human dendritic cells. Blood 2001; 98:2482–8. doi: 10.1182/blood.V98.8.2482 PMID: 11588046
Moris A, Nobile C, Buseyne F et al. DC-SIGN promotes exogenous MHC-I-restricted HIV-1 antigen presentation. Blood 2004; 103:2648–54. doi: 10.1182/blood-2003-07-2532 PMID: 14576049
Buseyne F, Le Gall S, Boccaccio C et al. MHC-I-restricted presentation of HIV-1 virion antigens without viral replication. Nat Med 2001; 7:344–9. doi: 10.1038/85493 PMID: 11231634
Geijtenbeek TB, Engering A, Van Kooyk Y. DC-SIGN, a C-type lectin on dendritic cells that unveils many aspects of dendritic cell biology. J Leukoc Biol 2002; 71:921–31. PMID:12050176
Geijtenbeek TB, Kwon DS, Torensma R et al. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 2000; 100:587–97. doi:10.1016/S0092-8674(00)80694-7 PMID: 10721995
Jameson B, Baribaud F, Pohlmann S et al. Expression of DC-SIGN by dendritic cells of intestinal and genital mucosae in humans and rhesus macaques. J Virol 2002; 76:1866–75. doi: 10.1128/JVI.76.4.1866-1875.2002 PMID:11799181
Geijtenbeek TB, Torensma R, van Vliet SJ et al. Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. Cell 2000; 100:575–85. doi: 10.1016/S0092-8674(00)80693-5 PMID: 10721994
Geijtenbeek TB, van Duijnhoven GC, van Vliet SJ et al. Identification of different binding sites in the dendritic cell-specific receptor DC-SIGN for intercellular adhesion molecule 3 and HIV-1. J Biol Chem 2002; 277:11314–20. doi: 10.1074/jbc.M111532200 PMID: 11799126
Dalgleish AG. The immune response to HIV: potential for immunotherapy? Immunol Today 1995; 16:356–8. doi: 10.1016/0167-5699(95)80156-1 PMID:7576075
Matsuyama T, Kobayashi N, Yamamoto N. Cytokines and HIV infection: is AIDS a tumor necrosis factor disease? AIDS 1991; 5:1405–17. doi: 10.1097/00002030-199112000-00001 PMID:1814326
Aukrust P, Liabakk NB, Muller F et al. Serum levels of tumor necrosis factor-a (TNF-a) and soluble TNF receptors in human immunodeficiency virus type 1 infection. Correlation to clinical, immunologie, and virologie parameters. J Infect Dis 1994; 169:420–4. doi: 10.1093/infdis/169.2.420 PMID:7906293
Godfried MH, van der Poll T, Weverling GJ et al. Soluble receptors for tumor necrosis factor as predictor of progression to AIDS in asymptomatic human immunodeficiency virus type 1 infection. J Infect Dis 1994; 169:739–45. doi: 10.1093/infdis/169.4.739 PMID:7907641
Aukrust P, Frøland SS, Liabakk NB et al. Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood 1994; 84:2136–43. PMID:7919327
Achiron A, Margalit R, Hershkoviz R et al. Intravenous immunoglobulin treatment of experimental T-cell-mediated autoimmune disease. J Clin Invest 1994; 93:600–5. doi:10.1172/JCI117012 PMID:8113397
Aukrust P, Frøland SS, Liabakk NB et al. Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood 1994; 84:2136–43. PMID:7919327
Olsson I, Lantz M, Nilsson E et al. Isolation and characterization of a tumor necrosis factor binding protein from human urine. Eur J Haematol 1989; 42:270–5. doi:10.1111/j.1600-0609.1989.tb00111.× PMID:2924890
Van Zee KJ, Kohno T, Fischer E et al. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and protect against excessive tumor necrosis factor-a in vitro and in vivo. Proc Natl Acad Sci USA 1992; 89:4845–9. PMID:1317575
Vandenabeele P, Declercq W, Beyaert R et al. Two tumor necrosis factor receptors: structure and function. Trends Cell Biol 1995; 5:392–9. doi:10.1016/S0962-8924(00)89088-1 PMID:14732063
Mofenson LM, Bethel J, Moye J et al. Effect of intravenous immunoglobulin (IVIG) on CD4/ lymphocyte decline in HIV infected children in a clinical trial of IVIG infection prophylaxis. J Acquir Immune Defic Syndr 1993; 6:1103–13. PMID:8105072
Palella FJJ, Delaney KM, Moorman AC et al. Declining mor-bidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853–60. doi:10.1056/NEJM199803263381301 PMID:9516219
Mocroft A, Ledergerber B, Katlama C et al. Decline in the AIDS and death rates in the EuroSIDA study: An observational study. Lancet 2003; 362:22–9. doi:10.1016/S0140-6736(03)13802.0 PMID:12853195
Rutschmann OT, Opravil M, Iten A et al. A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study. AIDS 1998; 12:F71–7. doi:10.1097/00002030-199808000-00003 PMID:9631134
Kaplan G, Thomas S, Fierer DS et al. Thalidomide for the treat-ment of AIDS-associated wasting. AIDS Res Hum Retroviruses 2000; 16:1345–55. doi:10.1089/08892220050140892 PMID:11018854
Rizzardi GP, Vaccarezza M, Capiluppi B et al. Cyclosporin A in combination with HAART in primary HIV-1 infection. J Biol Regul Homeost Agents 2000; 14:79–81. PMID:10763900
Vermeulen JN, Prins JM, Bunnik E et al. Intravenous immunoglobulin (IVIG) treatment for modulation of immune activation in human immunodeficiency virus type 1 infected therapy-naive individuals. AIDS Res Hum Retroviruses 2007; 23:1348–53. doi:10.1089/aid.2006.0210 PMID:18184076
Yap PL et al. Does intravenous immune globulin have a role in HIV-infected patients?. Clin Exp Immunol 1994; 97(supp 1):59–67. PMID:8033437
Mofenson LM, Moye Jr J, Bethel J et al. Prophylactic intravenous immunoglobulin in HIV-infected children with CD4þ counts of 0.20 × 10(9)/L or more. Effect on viral, opportunistic, and bacterial infections. JAMA 1992; 268:483–8. doi:10.1001/jama.268.4.483 PMID:1352363
Spector SA, Gelber RD, McGrath N et al. A controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection. Pediatric AIDS Clinical Trials Group. N Engl J Med 1994; 331:1181–7. doi:10.1056/NEJM199411033311802 PMID:7935655
Kiehl MG, Stoll R, Broder M et al. controlled trial of intravenous immune globulin for the prevention of serious infections in adults with advanced human immunodeficiency virus infection. Arch Intern Med 1996; 156:2545–50. doi:10.1001/archinte.156.22.2545 PMID:8951297
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Landes Bioscience and Springer Science+Business Media
About this chapter
Cite this chapter
Bouhlal, H., Kaveri, S. (2012). Multi-Faceted Role of Naturally Occurring Autoantibodies in Fighting Pathogens. In: Lutz, H.U. (eds) Naturally Occurring Antibodies (NAbs). Advances in Experimental Medicine and Biology, vol 750. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-3461-0_8
Download citation
DOI: https://doi.org/10.1007/978-1-4614-3461-0_8
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-3460-3
Online ISBN: 978-1-4614-3461-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)